NVAX Q3 2019 Earnings — Novavax, Inc. Revenue & Financial Results | Market Cap Arena

NVAXNovavax, Inc.

$2B

Q3 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M-67.6% YoY

Gross Profit

$3M100.0% margin

Operating Income

-$15M-597.8% margin

Net Income

-$18M-719.7% margin

EPS (Diluted)

$-0.74

QoQ Revenue Growth

-25.3%

Cash Flow

Operating Cash Flow

-$32M

Free Cash Flow

-$33M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$165M

Total Liabilities

$355M

Stockholders' Equity

-$190M

Cash & Equivalents

$71M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$8M	-67.6%
Gross Profit	$3M	$8M	-67.6%
Operating Income	-$15M	-$42M	+64.2%
Net Income	-$18M	-$45M	+59.5%

Revenue Segments

Grant

$3M100%